Abstract
In the last years, α1 adrenoceptors (α1-AR) have been the subject of intense research, in part because receptor-binding studies and molecular biology have opened up new aspects of understanding but also because of the potential to find new drugs possibly acting toward pathophysiological processes where α1-AR are involved, such as benign prostatic hyperplasia (BPH) or hypertension. At present, arylpiperazines represent one of the most studied classes of molecules with affinity at α1-AR. In fact, a large amount of work has been done and reported, describing synthetic procedures, biological evaluation at both α1-AR and the corresponding subtypes, and structure-activity relationships (SARs). In this paper, a review based on a literature survey aimed at focusing on the structural properties that a compound should possess to show affinity toward α1-AR is presented. Moreover, the identification and optimization of the structural features of a hit compound derived from a pharmacophore-based database search, leading to a new class of arylpiperazinylalkyl pyridazinone derivatives with α1-AR affinity is reported.
Keywords: arylpiperazine, 1-adrenergic receptor, alpha1-ar, pyridazinone derivative
Current Medicinal Chemistry
Title: Arylpiperazines with Affinity Toward a1-Adrenergic Receptors
Volume: 9 Issue: 13
Author(s): F. Manetti, F. Corelli, G. Strappaghetti and M. Botta
Affiliation:
Keywords: arylpiperazine, 1-adrenergic receptor, alpha1-ar, pyridazinone derivative
Abstract: In the last years, α1 adrenoceptors (α1-AR) have been the subject of intense research, in part because receptor-binding studies and molecular biology have opened up new aspects of understanding but also because of the potential to find new drugs possibly acting toward pathophysiological processes where α1-AR are involved, such as benign prostatic hyperplasia (BPH) or hypertension. At present, arylpiperazines represent one of the most studied classes of molecules with affinity at α1-AR. In fact, a large amount of work has been done and reported, describing synthetic procedures, biological evaluation at both α1-AR and the corresponding subtypes, and structure-activity relationships (SARs). In this paper, a review based on a literature survey aimed at focusing on the structural properties that a compound should possess to show affinity toward α1-AR is presented. Moreover, the identification and optimization of the structural features of a hit compound derived from a pharmacophore-based database search, leading to a new class of arylpiperazinylalkyl pyridazinone derivatives with α1-AR affinity is reported.
Export Options
About this article
Cite this article as:
Manetti F., Corelli F., Strappaghetti G. and Botta M., Arylpiperazines with Affinity Toward a1-Adrenergic Receptors, Current Medicinal Chemistry 2002; 9 (13) . https://dx.doi.org/10.2174/0929867023369961
DOI https://dx.doi.org/10.2174/0929867023369961 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aldose Reductase, Oxidative Stress and Diabetic Cardiovascular Complications
Cardiovascular & Hematological Agents in Medicinal Chemistry Protein-Tyrosine Phosphatase 1B as a Potential Drug Target for Obesity
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Protective Effects of Pomegranate in Endothelial Dysfunction
Current Pharmaceutical Design Sex Differences and Emerging New Risk Factors for Atherosclerosis and Its Thrombotic Complications
Current Pharmaceutical Design Approaches and Recent Trends in Gene Delivery for Treatment of Atherosclerosis
Recent Patents on Drug Delivery & Formulation Vascular Smooth Muscle Relaxation by a Lectin from Pisum arvense: Evidences of Endothelial NOS Pathway
Protein & Peptide Letters Familial Combined Hyperlipidaemia: Under - Defined and Under - Diagnosed?
Current Vascular Pharmacology An Overview of Emerging Immunotargets of Genitourinary Tumors
Current Drug Targets HCN Channels Modulators: The Need for Selectivity
Current Topics in Medicinal Chemistry Role of Radiopharmaceuticals in Development of Inhaled Drugs
Current Pharmaceutical Design New Insights in Mast Cell Modulation by Palmitoylethanolamide
CNS & Neurological Disorders - Drug Targets Angiotensin-(1-7), Angiotensin-Converting Enzyme 2 and Mas Receptor in Rat Polycystic Ovaries
Protein & Peptide Letters A Hopeful Prospect of Riociguat as a Soluble Guanylate Cyclase Stimulator for Management of Pressure Ulcers
Current Drug Discovery Technologies α-Glucosidase Inhibition, Antioxidant and Docking Studies of Hydroxycoumarins and their Mono and Bis O-alkylated/acetylated Analogs
Letters in Drug Design & Discovery Peroxisome Proliferator-Activated Receptor-γ: Master Regulator of Adipogenesis and Obesity
Current Stem Cell Research & Therapy “Tripping out” with the TRP Superfamily and TRPV1 for Novel Neuroprotection
Current Neurovascular Research Lower Serum Indirect Bilirubin Levels are Inversely Related to Carotid Intima-Media Thickness Progression
Current Neurovascular Research Role of AGEs-RAGE System in Cardiovascular Disease
Current Pharmaceutical Design MCI Patients in Europe: Medication and Comorbidities. The DESCRIPA Study
Current Alzheimer Research Simultaneous Bilateral Basal Ganglia Hemorrhage
Current Drug Delivery